Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Part of paid clinical trials in The Villages, Florida.

Sponsor
Amgen
Study ID
NCT07871409
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Maridebart cafraglutide — DRUG
    Administered subcutaneously.
  • Autoinjector — DEVICE
    The AI will be used by participants to self-administer SC doses of maridebart cafraglutide.

Study Details

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

Key Dates

First listed
Oct 13, 2026
Start date
Oct 28, 2026
Status verified
Oct 2026
Primary completion
Jun 16, 2027
Completion
Sep 8, 2027

Study Design

Enrollment
230 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Maridebart cafraglutide
    Participants will receive 8 total doses of subcutaneous (SC) injections of maridebart cafraglutide.

Primary Outcome Measure

Percentage of Participants Who Successfully Self-inject a Full Dose Among Those Who Attempted Injection at Each Home Administration [ Time Frame: Weeks 12, 16, and 20 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Charter Research - The VillagesThe VillagesFlorida32162-

Find similar trials in The Villages, FL

Related Studies